Merck & Co., Inc.

“Merck is a high-quality FCF generator facing a structural transition: Keytruda (>40% of revenue) faces biosimilar entry and IRA price negotiation from 2028, and the replacement pipeline — led by the Daiichi Sankyo ADC collaboration — remains unproven at scale. At 11.6x forward earnings the stock looks cheap in isolation, but that multiple prices near-term strength, not the trough, and the probability-weighted intrinsic value sits meaningfully below the current $113 price. Management has not bought the stock during its decline, pipeline M&A has been executed at full valuations, and the margin of safety is insufficient to justify aggressive capital commitment. TRACK: monitor for pipeline proof-of-concept data or a price decline to the $80–90 range that would offer genuine margin of safety.”